A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.» Read More
We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.
There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.
Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.
Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.
The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.
CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.
The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.
Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.
As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?
Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.
The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.
Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.